The results indicated that the recombinant MUC1-MBP vaccine enhanced MUC1-specific Th1 response and CTL killing activity, and increased the proportion of tumor infiltrating lymphocytes (CD4+ T and CD8+ T cells). This evidence concerns the gene MBP and neoplasm.